BridgeBio (BBIO) stock price, revenue, and financials

BridgeBio market cap is $8.6 b, and annual revenue was $8.25 m in FY 2020

$8.6 B

BBIO Mkt cap, 04-Jun-2021

$462 K

BridgeBio Revenue Q1, 2021
BridgeBio Net income (Q1, 2021)-171.1 M
BridgeBio EBIT (Q1, 2021)-167.5 M
BridgeBio Cash, 31-Mar-2021471.2 M
BridgeBio EV8.3 B

BridgeBio Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

40.6m8.2m

R&D expense

30.6m140.1m209.9m337.0m

General and administrative expense

13.3m43.6m94.4m145.7m

Operating expense total

43.9m183.7m304.3m482.7m

EBIT

(43.9m)(183.7m)(266.2m)(474.5m)

EBIT margin, %

(656%)(5752%)

Interest expense

13.0k2.5m

Interest income

39.0k2.0m8.9m4.0m

Investment income

(20.9m)

Pre tax profit

288.6m505.5m

Net Income

(43.8m)(169.5m)(288.6m)(505.5m)

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

26.7m8.1m462.0k

R&D expense

55.3m68.2m86.6m92.1m122.6m

General and administrative expense

23.5m34.3m38.0m36.0m45.4m

Operating expense total

78.8m102.5m124.6m128.1m168.0m

EBIT

(54.5m)(102.5m)(124.6m)(119.9m)(167.5m)

EBIT margin, %

(204%)(1476%)(36256%)

Interest expense

6.1m

Interest income

2.7m1.9m934.0k692.0k394.0k

Investment income

(6.6m)

Income tax expense

Net Income

(60.7m)(104.1m)(136.2m)(130.2m)(171.1m)

BridgeBio Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.0m436.1m363.8m356.1m

Prepaid Expenses

5.1m9.1m22.6m35.7m

Current Assets

97.1m445.2m568.6m642.8m

PP&E

440.0k1.6m5.6m20.3m

Total Assets

98.0m464.9m631.7m703.6m

Accounts Payable

1.9m13.5m8.9m8.9m

Short-term debt

8.0m5.3m

Current Liabilities

8.6m32.6m60.4m95.6m

Long-term debt

54.5m91.8m107.1m

Total Debt

54.5m99.8m112.4m

Total Liabilities

8.9m87.6m155.7m595.7m

Common Stock

1.4m1.6b124.0k125.0k

Preferred Stock

146.7m784.0m

Additional Paid-in Capital

848.1m1.0b

Retained Earnings

(61.4m)(170.6m)(440.0m)(888.8m)

Total Equity

(58.9m)(108.2m)473.7m106.3m

Financial Leverage

-1.7 x-4.3 x1.3 x6.6 x

BridgeBio Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(43.8m)(169.5m)(288.6m)(505.5m)

Depreciation and Amortization

260.0k245.0k

Accounts Payable

1.6m16.7m(4.7m)(735.0k)

Cash From Operating Activities

(40.5m)(136.6m)(253.6m)(399.7m)

Purchases of PP&E

(464.0k)(2.2m)(2.6m)(7.5m)

Cash From Investing Activities

(464.0k)(21.0m)(217.3m)(53.0m)

Dividends Paid

(997.0k)

Cash From Financing Activities

113.0m501.5m398.8m447.2m

Net Change in Cash

72.0m343.9m(72.0m)(5.5m)

Interest Paid

1.6m6.1m15.3m

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(204.4m)(104.1m)(240.3m)(370.5m)(171.1m)

Depreciation and Amortization

618.0k

Accounts Payable

(3.2m)4.2m4.0m547.0k1.8m

Cash From Operating Activities

(177.4m)(83.9m)(171.8m)(303.5m)(150.8m)

Purchases of PP&E

(891.0k)(4.5m)(4.8m)(5.4m)(2.0m)

Cash From Investing Activities

(200.4m)38.0m(91.0m)(136.0m)(282.1m)

Dividends Paid

(997.0k)

Cash From Financing Activities

355.9m439.2m439.9m442.7m547.9m

Net Change in Cash

(21.8m)393.3m177.1m3.2m115.1m

Interest Paid

4.3m2.1m4.1m13.3m8.9m

BridgeBio Ratios

USDFY, 2017

Financial Leverage

-1.7 x